Impact of Ticagrelor Re-load on Pharmacodynamic Profiles in Patients on Maintenance Ticagrelor Therapy
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2015
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary)
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 17 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Apr 2014 Planned End Date changed from 1 Feb 2014 to 1 Apr 2014 as reported by cliicalTrial.gov.